Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5876901 | 0.81 | LRRK2 (0.40) | LMNAMAPK10HCAR2HTR7 | |
| SCHEMBL5876644 | 0.81 | MAPK10 (0.46) | LMNAMAPK10HCAR2HTR7 | |
| SCHEMBL5877396 | 0.80 | LMNA (0.33) | LMNAMAPK10HCAR2HTR7 | |
| SCHEMBL5877629 | 0.79 | LMNA (0.33) | LMNAMAPK10HCAR2HTR7 | |
| SCHEMBL5877207 | 0.76 | HDAC4 (0.37) | HDAC4LMNAMAPK10HCAR2HTR7 | |
| SCHEMBL5876657 | 0.76 | HDAC4 (0.37) | HDAC4LMNAMAPK10HCAR2HTR7 | |
| SCHEMBL5877114 | 0.76 | MKNK1 (0.40) | LMNAMAPK10HCAR2HTR7 | |
| SCHEMBL5875946 | 0.76 | ADORA2A (0.38) | LMNAMAPK10HCAR2HTR7 | |
| SCHEMBL5875877 | 0.75 | NISCH (0.41) | LMNAMAPK10HCAR2HTR7 | |
| SCHEMBL5875924 | 0.73 | HCAR2 (0.38) | LMNAMAPK10HCAR2HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119115-B2 | Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology | AVENTIS PHARMA S.A. (FR) | 2006-10-10 | — | — | US | disclosed |
| US-20040162276-A1 | Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology | AVENTIS PHARMA S.A. (FR) | 2004-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162276-A1 | Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology | IDO1, IDO2, INMT | HDAC4 989/4885LMNA 4385/4885MAPK10 3260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.